The FDA has issued a safety alert about the drug Advandia, which is used to treat type-2 diabetes. Data from some trials of the drug show that patients taking Advandia have a potentially serious increased risk of heart attack and heart-related death. Other studies show contradictory results. As of right now, the FDA is not requiring GlaxoSmithKline, the maker of Advandia, to take any action regarding the drug. Rather, doctors and patients should consider this information when making treatment decisions, particularly with diabetes patients who have underlying heart disease or a high heart attack risk. The FDA plans to analyze multiple data sources regarding Advandia and release its results as soon as possible.
Comments are closed.